Key result
Polypharmacy linked to potential drug-drug interactions affecting ~69% of admitted psychiatric patients.
Why the study?
Combined medications can result in life-threatening potential drug-drug interactions causing severe clinical outcomes, prompting the evaluation of their prevalence and associated factors among admitted psychiatric patients.
Cross-Sectional (n=325)
Yes
A high prevalence (68.9%) of clinically significant potential drug-drug interactions was found among admitted psychiatric patients, driven by older age, polypharmacy, and longer hospital stays.
Answers are grounded in this paper and cite their sources.
May inform pDDI screening in psychiatric inpatients; leaves open whether interventions reduce adverse events.
Background: Prescribing medications without potential drug-drug interactions (pDDIs) is one of the components of the rational use of medications. However, taking combined medications has resulted in life-threatening pDDIs, which are causing severe clinical outcomes for patients. This study was aimed at assessing the prevalence of pDDIs and associated factors in admitted patients with psychiatric disorders. Methods: An institution-based multicenter cross-sectional study was conducted among patients with psychiatric disorders admitted to a selected hospital in Northwest Ethiopia. Samples were approached through a systematic sampling method. The Statistical Package for the Social Sciences (SPSS) version 26 was used to analyze the data. Logistic regression was applied to determine the association of variables with pDDIs. A p-value of < 0.05 was statistically significant. Results: Out of 325 study participants, more than half (52.9%) were females, with a median age of 61 years. Overall, more than two-thirds (68.9%) were exposed to at least one clinically significant, either moderate or major level of pDDIs. Nearly one-fourth (23.2%) of participants had at least one major level of pDDIs. Older patients were found more likely to have pDDIs compared to younger patients (p = 0.043). Similarly, patients with a higher number of prescribed medications (p = 0.001) and patients with longer hospital admissions (p = 0.004) were found more likely to be exposed to pDDIs than their counterparts. Conclusion: In this study, a significant number of admitted patients with psychiatric problems encountered clinically significant pDDIs. As a result, healthcare providers could assess and follow patients with a combination of medications that potentially have a drug-drug interaction outcome.
No takes yet. Share an insight, caveat, or question.
Dagnew et al. (2022) conducted a cross-sectional in Psychiatric disorders (n=325). Combination of medications was evaluated on Prevalence of clinically significant potential drug-drug interactions (pDDIs). In admitted patients with psychiatric disorders, 68.9% were exposed to at least one clinically significant potential drug-drug interaction, with polypharmacy (≥5 medications) increasing this risk.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: